Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-12, Stock:LLY, The news for the past five days is as follows:
2019-06-05: NEWS1: Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction.NEWS2: Eli Lilly gets FDA approval for cluster headache medication.NEWS3: How Merck reached new ground in the fight against cancer.NEWS4: The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache.NEWS5: Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology.NEWS6: Eli Lilly&apos;s Emgality gets FDA approval for episodic cluster headaches.NEWS7: FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks.
2019-06-06: NEWS1: Incyte Begins Phase III Study for Treatment of Duct Cancer.NEWS2: Incyte Begins Phase III Study for Treatment of Duct Cancer.NEWS3: Incyte Begins Phase III Study for Treatment of Duct Cancer.NEWS4: Lilly's Emgality Gets FDA Approval for Cluster Headache.NEWS5: Lilly's Emgality Gets FDA Approval for Cluster Headache.NEWS6: Lilly's Emgality Gets FDA Approval for Cluster Headache.NEWS7: Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology.
2019-06-07: NEWS1: Here’s What Hedge Funds Think About Eli Lilly and Company (LLY).NEWS2: Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache.
2019-06-10: NEWS1: Top Analyst Reports for Oracle, Eli Lilly & Mondelez.NEWS2: Top Analyst Reports for Oracle, Eli Lilly & Mondelez.NEWS3: Top Analyst Reports for Oracle, Eli Lilly & Mondelez.NEWS4: Notable Two Hundred Day Moving Average Cross - LLY.NEWS5: Notable Two Hundred Day Moving Average Cross - LLY.NEWS6: New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria.NEWS7: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca.NEWS8: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca.NEWS9: Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet.NEWS10: Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet.NEWS11: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca.NEWS12: Eli Lilly stock down 2.4% after Trulicity trial misses investors&apos; expectations.NEWS13: Eli Lilly Stock Is Falling and Novo Nordisk Is Rising on Diabetes-Drug Results.NEWS14: Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet.NEWS15: Thor Industries and Eli Lilly Offer a Tale of Two Stocks.NEWS16: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS17: Better Buy: Eli Lilly vs. AbbVie.NEWS18: Better Buy: Eli Lilly vs. AbbVie.
2019-06-11: NEWS1: The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest.NEWS2: Merck (MRK) to Buy Private Biotech Tilos for Up to $773M.NEWS3: Merck (MRK) to Buy Private Biotech Tilos for Up to $773M.NEWS4: Lilly Announces Tradjenta Cardiovascular Outcome Study Data.NEWS5: Lilly Announces Tradjenta Cardiovascular Outcome Study Data.NEWS6: Lilly Announces Tradjenta Cardiovascular Outcome Study Data.NEWS7: Merck (MRK) to Buy Private Biotech Tilos for Up to $773M.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS9: The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering.NEWS10: Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology.NEWS11: Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®.

Answer: Rise